VistaGen Therapeutics Inc (VTGN) Stock Analysis

VistaGen Therapeutics Inc (VTGN) is a publicly traded company in the HEALTHCARE sector. It trades at $0.58, carries a market capitalization of $25.65M. This page summarizes the public market data, fundamentals, and frequently asked questions for VTGN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.58
• Market Cap: $25.65M
• EPS: $-1.90
• 52-Week High: $5.14
• 52-Week Low: $0.43

Market Sentiment

VistaGen Therapeutics Inc currently has a Neutral sentiment score of -0.08.

About VistaGen Therapeutics Inc

VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for anxiety, depression, and other central nervous system disorders. Based in South San Francisco, California, the company is advancing its proprietary drug candidates, notably AV-101, aimed at fulfilling significant unmet needs in the mental health sector. With a strong focus on neuropharmacology and a promising pipeline, VistaGen is positioned as a key player in the rapidly ...

GNG Research Analysis

GNG Research scores VistaGen Therapeutics Inc (VTGN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for VTGN.

Frequently Asked Questions

Does VTGN pay dividends?

VistaGen Therapeutics Inc (VTGN) does not currently pay a regular dividend.

What is VTGN's market cap?

VistaGen Therapeutics Inc (VTGN) has a market capitalization of $25.65M with a current stock price of $0.58.